<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gimisis, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Synthesis of N-Glucopyranosidic Derivatives as Potential Inhibitors that Bind at the Catalytic Site of Glycogen Phosphorylase</style></title><secondary-title><style face="normal" font="default" size="100%">Mini-Reviews Med. Chem.</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">oct</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.eurekaselect.com/openurl/content.php?genre=article{&amp;}issn=1389-5575{&amp;}volume=10{&amp;}issue=12{&amp;}spage=1127</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">12</style></number><volume><style face="normal" font="default" size="100%">10</style></volume><pages><style face="normal" font="default" size="100%">1127–1138</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;div class=&quot;page&quot;&gt;
&lt;div class=&quot;layoutArea&quot;&gt;
&lt;div class=&quot;column&quot;&gt;
&lt;p&gt;&lt;span style=&quot;font-size: 9.000000pt; font-family: 'TimesNewRomanPSMT';&quot;&gt;Glycogen phosphorylase (GP) is a promising molecular target for the treatment of Type 2 diabetes. The design of potential inhibitors for the catalytic site of the enzyme is based on the high affinity for &lt;/span&gt;&lt;span style=&quot;font-size: 9.000000pt; font-family: 'TimesNewRomanPSMT';&quot;&gt;&lt;/span&gt;&lt;span style=&quot;font-size: 9.000000pt; font-family: 'TimesNewRomanPSMT';&quot;&gt;-&lt;/span&gt;&lt;span style=&quot;font-size: 8.000000pt; font-family: 'TimesNewRomanPSMT';&quot;&gt;D&lt;/span&gt;&lt;span style=&quot;font-size: 9.000000pt; font-family: 'TimesNewRomanPSMT';&quot;&gt;-glucopyranose and the pres- ence of a &lt;/span&gt;&lt;span style=&quot;font-size: 9.000000pt; font-family: 'TimesNewRomanPSMT';&quot;&gt;&lt;/span&gt;&lt;span style=&quot;font-size: 9.000000pt; font-family: 'TimesNewRomanPSMT';&quot;&gt;-cavity that extends from the sugar anomeric position forming a 15 x 7.5 x 10 Å available space. This review is focused on our efforts towards the design and synthesis of various families of potential inhibitors, including &lt;/span&gt;&lt;span style=&quot;font-size: 9.000000pt; font-family: 'TimesNewRomanPS'; font-style: italic;&quot;&gt;N&lt;/span&gt;&lt;span style=&quot;font-size: 9.000000pt; font-family: 'TimesNewRomanPSMT';&quot;&gt;-&lt;/span&gt;&lt;span style=&quot;font-size: 9.000000pt; font-family: 'TimesNewRomanPSMT';&quot;&gt;&lt;/span&gt;&lt;span style=&quot;font-size: 9.000000pt; font-family: 'TimesNewRomanPSMT';&quot;&gt;-&lt;/span&gt;&lt;span style=&quot;font-size: 8.000000pt; font-family: 'TimesNewRomanPSMT';&quot;&gt;D&lt;/span&gt;&lt;span style=&quot;font-size: 9.000000pt; font-family: 'TimesNewRomanPSMT';&quot;&gt;- glucopyranosyl oxamic acid esters and oxamides, &lt;/span&gt;&lt;span style=&quot;font-size: 9.000000pt; font-family: 'TimesNewRomanPS'; font-style: italic;&quot;&gt;N&lt;/span&gt;&lt;span style=&quot;font-size: 9.000000pt; font-family: 'TimesNewRomanPSMT';&quot;&gt;-&lt;/span&gt;&lt;span style=&quot;font-size: 9.000000pt; font-family: 'TimesNewRomanPSMT';&quot;&gt;&lt;/span&gt;&lt;span style=&quot;font-size: 9.000000pt; font-family: 'TimesNewRomanPSMT';&quot;&gt;-&lt;/span&gt;&lt;span style=&quot;font-size: 8.000000pt; font-family: 'TimesNewRomanPSMT';&quot;&gt;D&lt;/span&gt;&lt;span style=&quot;font-size: 9.000000pt; font-family: 'TimesNewRomanPSMT';&quot;&gt;-glucopyranosylaminocarbonyl L-aminoacids and peptides, as well as glucose-derived purine and pyrimidine nucleosides, spiro- and other bicyclic derivatives. Kinetic and crystallo- graphic study of the interactions of these inhibitors with GP has increased our understanding of the importance of the various functional groups within the catalytic site and has pointed the way towards the &lt;/span&gt;&lt;span style=&quot;font-size: 9.000000pt; font-family: 'TimesNewRomanPS'; font-style: italic;&quot;&gt;in silico &lt;/span&gt;&lt;span style=&quot;font-size: 9.000000pt; font-family: 'TimesNewRomanPSMT';&quot;&gt;prediction and design of potent inhibitors, which are both synthetically viable and pharmacologically relevant. &lt;/span&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</style></abstract></record></records></xml>